|
Market Closed -
Bombay S.E.
05:02:34 2026-11-18 am EST
|
5-day change | 1st Jan Change | ||
| 2,638.00 INR | -1.36% |
|
-3.24% | +6.76% |
Company Valuation: GlaxoSmithKline Pharmaceuticals Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 281,714 | 224,319 | 329,173 | 487,432 | 386,822 | 446,893 | - | - |
| Change | - | -20.37% | 46.74% | 48.08% | -20.64% | 15.53% | - | - |
| Enterprise Value (EV) | 256,351 | 207,663 | 329,173 | 487,432 | 386,822 | 446,893 | 446,893 | 446,893 |
| Change | - | -18.99% | 58.51% | 48.08% | -20.64% | 15.53% | 0% | 0% |
| P/E | 16.6x | 36.7x | 55.8x | 52.5x | 37.3x | 38x | 33.3x | 30.4x |
| PBR | 10.6x | 12.9x | 18.5x | 25x | 17.1x | 16.9x | 14.3x | 12.6x |
| PEG | - | -0.6x | -16.49x | 0.9x | 3.2x | 2.8x | 2.4x | 3.15x |
| Capitalization / Revenue | 8.59x | 6.9x | 9.53x | 13x | 10.1x | 10.3x | 9.22x | 8.43x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 10.3x | 9.22x | 8.43x |
| EV / EBITDA | 0x | 0x | 0x | 0x | 0x | 30.1x | 26.3x | 24.1x |
| EV / EBIT | 0x | 0x | 0x | 0x | 0x | 30.2x | 26.3x | 24.7x |
| EV / FCF | 0x | 0x | 0x | 0x | 0x | 37.2x | 33.2x | 29.6x |
| FCF Yield | 2.75% | 1.96% | 1.67% | 2.6% | 2.19% | 2.69% | 3.01% | 3.38% |
| Dividend per Share 2 | 30 | 32 | 32 | 42 | 57 | 29.5 | 29.5 | 35 |
| Rate of return | 1.8% | 2.42% | 1.65% | 1.46% | 2.5% | 1.12% | 1.12% | 1.33% |
| EPS 2 | 100 | 36.05 | 34.83 | 54.76 | 61.15 | 69.37 | 79.15 | 86.8 |
| Distribution rate | 30% | 88.8% | 91.9% | 76.7% | 93.2% | 42.5% | 37.3% | 40.3% |
| Net sales 1 | 32,780 | 32,517 | 34,537 | 37,492 | 38,217 | 43,335 | 48,469 | 52,982 |
| EBITDA 1 | 8,273 | 8,043 | 9,087 | 11,774 | 13,092 | 14,838 | 16,983 | 18,562 |
| EBIT 1 | 7,592 | 7,385 | 8,390 | 11,106 | 12,428 | 14,820 | 16,987 | 18,102 |
| Net income 1 | 16,947 | 6,107 | 5,900 | 9,276 | 10,360 | 11,850 | 13,407 | 14,708 |
| Net Debt | -25,363 | -16,656 | - | - | - | - | - | - |
| Reference price 2 | 1,662.95 | 1,324.15 | 1,943.10 | 2,877.30 | 2,283.40 | 2,638.00 | 2,638.00 | 2,638.00 |
| Nbr of stocks (in thousands) | 169,406 | 169,406 | 169,406 | 169,406 | 169,406 | 169,406 | - | - |
| Announcement Date | 5/16/22 | 5/17/23 | 5/17/24 | 5/13/25 | 5/13/26 | - | - | - |
1INR in Million2INR
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 38.83x | - | - | 1.1% | 4.88B | ||
| 41.43x | 14.03x | 29.73x | 0.48% | 1,261B | ||
| 40.79x | 6.85x | 19.26x | 1.91% | 671B | ||
| 37.33x | 8.57x | 17.72x | 2.36% | 518B | ||
| 21.83x | 5.29x | 13.24x | 2.47% | 387B | ||
| 101.76x | 5.82x | 24.8x | 2.37% | 353B | ||
| 23.99x | 5.78x | 14.05x | 2.75% | 300B | ||
| 23.93x | 4.79x | 13.46x | 1.83% | 283B | ||
| 23.64x | 7.27x | 13.36x | 2.2% | 248B | ||
| -40.04x | 7.4x | 46.61x | 1.94% | 211B | ||
| Average | 31.35x | 7.31x | 21.36x | 1.94% | 424B | |
| Weighted average by Cap. | 36.56x | 8.81x | 22.37x | 1.7% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GLAXO Stock
- Valuation GlaxoSmithKline Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
















